Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan)

Dermatology

Volumn 219, Issue 2, 2009, Pages 171-173

  Gholam, P ^a   Sehr, T ^a   Enk, A ^a   Hartmann, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bosentan; Digital ulcers; Endothelin receptor antagonist; Sitaxentan; Systemic sclerosis

Indexed keywords

AMLODIPINE; ANTINUCLEAR ANTIBODY; CYCLOSPORIN; ISOSORBIDE DINITRATE; METHOTREXATE; PREDNISOLONE; SCL 70 ANTIBODY; SITAXSENTAN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DOPPLER ECHOGRAPHY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ECHOCARDIOGRAPHY; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS SCINTISCANNING; FEMALE; FINGER; FOREARM; HEMATOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; OFF LABEL DRUG USE; OINTMENT; PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCAR; SCLERODERMA; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS; TREATMENT DURATION; ULCER; ULCER HEALING;

ADULT; AMLODIPINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FINGERS; FOLLOW-UP STUDIES; HAND DERMATOSES; HUMANS; METHOTREXATE; RECEPTOR, ENDOTHELIN A; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN ULCER; TREATMENT OUTCOME;

EID: 69349089567     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228318     Document Type: Article

References (8)

1. Baroni SS, et al: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667-2676. (Pubitemid 43920840)
2. Korn JH, et al: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985-3993.
3. Roldan R, et al: Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children. J Rheumatol 2006; 33: 2538-2540. (Pubitemid 46067838)
4. Chamaillard M, et al: Bosentan as a rescue therapy in scleroderma refractory digital ulcers. Arch Dermatol 2007; 143: 125-126. (Pubitemid 46143219)
5. Tillon J, et al: Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy. Br J Dermatol 2006; 154: 1000-1002.
6. Garcia de la Pena-Lefebvre P, et al: Longterm experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford) 2008; 47: 464-466.
7. Galie N, Manes A, Branzi A: The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-237. (Pubitemid 38091763)
8. Opitz CF, et al: Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 2008; 29: 1936-1948.